- Since 2019, NSG BioLabs has been a leader in co-working lab
spaces in Singapore, and has
nurtured over 40 biotech companies, of which the startups have
achieved nearly US$400 million
funding in total alongside significant business milestones
- NSG BioLabs' partnerships with EnterpriseSG and Merck enable
the company to enhance its offerings to residents, with the goal of
supporting its residents' innovation and R&D
endeavours
- NSG BioLabs has also secured strategic investment of
US$14.5 million, led by Celadon
Partners, an Asian private equity firm and ClavystBio, a life
science investor and venture builder set up by Temasek
- Fresh funding will be used to augment NSG BioLabs'
infrastructure, services, and benefits for residents, as well as
support the expansion of its co-working laboratory and office
spaces
SINGAPORE, May 7, 2024
/PRNewswire/ -- NSG BioLabs, Singapore's largest provider of biotech
co-working laboratory and office space, announces partnerships with
Enterprise Singapore (EnterpriseSG), the Singapore government agency championing
enterprise development, and Merck, a leading science and technology
company, to bolster the biotech landscape by providing needed
resources such as funding, expertise and networks to advance
startup research and development (R&D). The company also
successfully concluded a US$14.5
million financing round led by Celadon Partners, an Asian
private equity firm, and ClavystBio, a life science investor and
venture builder set up by Temasek to accelerate the
commercialisation of breakthrough ideas to health impact. These
achievements reaffirm NSG BioLabs' strength and expertise in
providing high-quality, well-managed, and turnkey Biosafety Level 2
(BSL-2) certified laboratory and office spaces. Moreover, these
milestones underscore NSG BioLabs as an ecosystem catalyst,
providing value-add services and networks, which are important in
driving scientific innovation and business growth.
Since 2019, NSG BioLabs has been assisting innovators in
creating impactful solutions in the health, biomedical, agrifood,
and industrial biotechnology sectors, working in areas such as
precision medicine, nucleic acids, AI-enabled drug discovery, and
synthetic biology. With the largest co-working biotech laboratory
and office footprint in Singapore,
coupled with extensive networks with partners, suppliers and
industry experts, NSG BioLabs has helped over 40 companies as
residents. The company's residents include several
multi-billion-dollar multinationals as well as many promising
startups that have achieved key milestones. The startup residents
alone have successfully raised nearly US$400
million in funding and supported hundreds of jobs.
"NSG BioLabs is committed to supporting innovators and proud to
have helped in Singapore's growing
biotech ecosystem. Our partnerships with EnterpriseSG and Merck
signify the importance of a collaborative spirit, and we hope to
spur greater collaboration among other stakeholders to benefit the
biotech industry in Singapore and
the Asia Pacific region," said
Daphne Teo, CEO and Founder of NSG
BioLabs, "Also, we are thankful
for the recognition from our strategic investors, Celadon Partners
and ClavystBio, and look forward to further empowering our
residents in their innovation efforts through expanded facilities,
enhanced value-add offerings, and greater exposure to valuable
industry networking and mentorship experiences."
NSG BioLabs has been part of EnterpriseSG's Startup SG
Accelerator programme since 2019[1]. NSG BioLabs is
excited to announce its renewed partnership with EnterpriseSG to
invest in and nurture more high-potential biotech startups, in
particular, expanding support for those with promising innovations
in fields such as precision medicine, with the aim of fast-tracking
the development and commercialisation of such deep tech
solutions.
"Singapore's biotech landscape
has evolved significantly, with a burgeoning community of global
startups and doubled healthtech deals in 2023[2].
EnterpriseSG will continue to work with industry partners like NSG
BioLabs to drive the development of new deep tech innovations such
as AI-enabled platforms and targeted therapies by providing patient
capital, infrastructure and expertise. This will strengthen
Singapore's edge in precision
medicine and revolutionise healthcare delivery," said Dr
Clarice Chen, Director of Healthcare
and Biomedical, EnterpriseSG.
To further its mission of supporting biotech innovators, NSG
BioLabs also closed a US$14.5 million
strategic investment round, led by Celadon Partners with
participation from ClavystBio. With these fresh funds, NSG BioLabs
intends to enhance its product and services and to introduce
additional facilities to meet the growing demands of biotech
startups and multinational companies in Singapore and Southeast Asia.
"As the Southeast Asia biotech
sector experiences tremendous growth driven by healthcare needs, we
are confident that NSG BioLabs' innovative co-working model can
offer compelling solutions for biotech startups and companies
across the region. NSG BioLabs' dedication to empowering companies
to fast-track their research and development efforts is
commendable," said Donald Tang,
Managing Partner at Celadon Partners.
"ClavystBio is excited to foster the growth of Singapore's life science ecosystem through our
support of NSG BioLabs, and its resident startups. This investment
reinforces ClavystBio's mission to accelerate breakthrough science
into health impact through venture building, and strategic
partnerships," said Khoo Shih Ph.D. Chief Executive Officer at
ClavystBio.
As a key platform in the region with established and growing
scale, NSG BioLabs fosters mutually beneficial connections between
its residents and other key parties. To further enable its
residents to develop, grow and scale-up, NSG BioLabs has secured a
partnership with Merck to provide its residents special terms for
Merck's reagents, and equipment in life sciences. The partnership
also includes preferential access to biopharma processing expertise
and consultation for scaling-up production.
Since its inception, NSG BioLabs has been supporting biotech
startups and multinational companies by providing BSL-2 certified
private and shared laboratory spaces and offices, equipment, as
well as, privileged access with service providers and suppliers,
and community engagement. After its first site opening in
November 2019, NSG BioLabs expanded
with its second site in August 2021,
and recently 2023 with its third site. Now, with three sites
totaling 35,000 square feet, NSG BioLabs cements its space as a key
hub for biotech innovation. As one of the largest private biotech
incubators in the region, coupled with its recent partnerships and
strategic investors, NSG BioLabs is poised to enhance its value-add
offerings of infrastructure, services, and networks to its growing
community.
About NSG BioLabs
Founded with a focus on supporting biotech innovation, NSG
BioLabs offers state-of-the-art equipment, efficient operations,
capital efficiency, the expertise of world-class teams and global
networks to assist life sciences companies. The conducive R&D
environment contains fully-equipped, certified BSL-2 laboratory and
office infrastructure across 35,000 sq ft in the prime location of
Biopolis in Singapore.
By providing access to high-quality infrastructure, its
extensive partner network, community, and value-add benefits, NSG
BioLabs ensures that companies, ranging from emerging biotech
startups to multinational companies, can rapidly and efficiently
execute on their cutting-edge research and development ecosystem
in Singapore, leading to the innovation of revolutionary
technologies and products that translate into breakthrough biotech
ventures and impact for patients.
For more information, visit www.nsgbio.com
[1]
EnterpriseSG's Startup SG Accelerator supports startup enablers,
such as incubators and accelerators to nurture the development of
high potential Singapore-based startups.
|
[2] Singapore Venture Funding
Landscape 2023 by DealStreetAsia
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nsg-biolabs-fuels-biotech-innovation-in-singapore-and-southeast-asia-through-partnerships-with-enterprisesg-and-merck-alongside-investments-from-celadon-partners-and-clavystbio-302137843.html
SOURCE NSG BioLabs